Clinical Trial: First-line Therapy With EGFR-TKI Combined With Trastuzumab Rezetecan for Advanced NSCLC Harboring EGFR Mutations Concomitant With HER2 Alterations

U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07699952) titled 'First-line Therapy With EGFR-TKI Combined With Trastuzumab Rezetecan for Advanced NSCLC Harboring EGFR Mutations Concomitant With HER2 Alterations' on July 07.

Brief Summary: To explore the efficacy and safety of first-line EGFR-TKI combined with Trastuzumab Rezetecan in advanced NSCLC patients harboring EGFR mutations with concomitant HER2 genomic alterations or HER2 protein expression (1+/2+/3+)

Study Start Date: July 09

Study Type: INTERVENTIONAL

Condition: Lung Cancer (NSCLC) EGFR Activating Mutation HER2

Intervention: DRUG: EGFR-TKI combined with HER2 ADC

EGFR-TKI combined with Trastuzumab Rezetecan(HER2 ADC)

Recruitmen...